Publication
Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.
Susan Bal, Myo Htut, Omar Nadeem, Larry D Anderson, Tara Gregory, Mehmet Hakan Koçoğlu, Adriana C Rossi, Tom Martin, Daniel N Egan, Luciano J Costa, Hongxiang Hu, Jinjie Chen, Shaoyi Li, Lisa M Kelly, Naomey Sarkis, Safiyyah Ziyad, Kristina M Jordahl, Wei-Ming Kao, Allison J Kaeding, Michael R Burgess, Jesus G Berdeja
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Patients with relapsed/refractory multiple myeloma (RRMM) have limited treatment options. Arlocabtagene autoleucel (arlo-cel; BMS-986393) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting G protein-coupled receptor class C group 5 member D (GPRC5D). This phase 1,…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT04674813registry_reference1.00
Candidate 1
- cancerMultiple Myelomadictionary0.60
Registered trialsNCT04674813
Curated evidence
Evidence citing this paper (0)
Data not yet available